Foghorn Therapeutics Inc.

NASDAQ: FHTX · Real-Time Price · USD
5.02
-0.13 (-2.43%)
At close: Aug 15, 2025, 3:59 PM
5.07
1.00%
After-hours: Aug 15, 2025, 05:10 PM EDT

Foghorn Therapeutics Income Statement

Financials in USD. Fiscal year is January - December.
Fiscal Year Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022 Q2 2022 Q1 2022 Q4 2021 Q3 2021 Q2 2021 Q1 2021
Period Ending Jun 30, 2025 Mar 31, 2025 Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021
Revenue
7.56M 5.95M 2.86M 7.81M 6.89M 5.05M 5.77M 17.48M 5.6M 5.31M 4.18M 6.63M 4.49M 3.92M 713K 41K 279K 286K
Cost of Revenue
900K n/a n/a n/a n/a n/a 852K 864K 2.17M n/a 19.23K 1.1M 25.97M 1.93M 1.9M 20.49M 18.64M 18.73M
Gross Profit
6.66M 5.95M 2.86M 7.81M 6.89M 5.05M 4.92M 16.61M 3.43M 5.31M 4.16M 5.53M -21.48M 2M -1.19M -20.45M -18.36M -18.44M
Operating Income
-21.1M -22.91M -24M -23.85M -26.63M -28.19M -25.46M -17.08M -32.05M -33.32M -31.89M -28.26M -29.19M -27.8M -28.08M -26.26M -23.26M -23.13M
Interest Income
2.31M 2.69M 3.1M 3.5M 2.87M 2.44M 2.66M 2.75M 2.79M 2.67M 420K 1.84M 1.23M 235K 598K 680K 645K 630K
Pretax Income
-17.94M -18.83M -19.5M -19.12M -22.98M -25.02M -22.12M -13.61M -28.55M -29.93M -28.89M -25.77M -27.31M -26.91M 72.08M -26.08M -23.11M -22.99M
Net Income
-17.94M -18.83M -19.5M -19.12M -22.98M -25.02M -24.11M -14.35M -29.49M -30.49M -34.13M -23.28M -27.31M -26.02M 170.75M -26.08M -23.11M -22.99M
Selling & General & Admin
6.86M 7.24M 6.35M 6.97M 7.33M 7.71M 7.02M 8.31M 8.4M 8.64M 7.86M 7.96M 7.7M 7.22M 6.33M 5.81M 4.9M 4.69M
Research & Development
20.89M 21.63M 20.51M 24.69M 23.8M 25.53M 23.35M 26.25M 29.25M 29.98M 28.21M 26.93M 25.97M 24.51M 22.46M 20.49M 18.64M 18.73M
Other Expenses
n/a n/a n/a n/a 2.4M n/a n/a 721K 712K n/a n/a n/a n/a n/a n/a n/a n/a n/a
Operating Expenses
27.75M 28.86M 26.86M 31.66M 33.52M 33.24M 30.38M 34.56M 37.65M 38.63M 36.07M 34.89M 33.68M 31.72M -73.16M 26.3M 23.54M 23.42M
Interest Expense
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a 426K 499K 495K 486K
Selling & Marketing Expenses
n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a n/a
Cost & Expenses
28.65M 28.86M 26.86M 31.66M 33.52M 33.24M 31.23M 34.56M 37.65M 38.63M 36.07M 34.89M 33.68M 31.72M -73.16M 26.3M 23.54M 23.42M
Income Tax Expense
n/a n/a n/a n/a n/a n/a 1.99M 738K 942K 560K 5.25M -2.49M n/a -890K -98.68M n/a n/a n/a
Shares Outstanding (Basic)
62.98M 62.85M 62.6M 62.6M 51.58M 42.43M 42.28M 42.03M 41.83M 41.81M 41.8M 41.67M 41.52M 41.37M 36.97M 36.97M 36.85M 36.82M
Shares Outstanding (Diluted)
62.98M 62.85M 62.6M 62.6M 51.58M 42.43M 42.28M 42.03M 41.83M 41.81M 41.8M 41.67M 41.52M 41.37M 36.97M 36.97M 36.85M 36.82M
EPS (Basic)
-0.28 -0.3 -0.31 -0.31 -0.45 -0.59 -0.57 -0.34 -0.7 -0.73 -0.82 -0.56 -0.66 -0.63 4.62 -0.71 -0.63 -0.62
EPS (Diluted)
-0.28 -0.3 -0.31 -0.31 -0.45 -0.59 -0.57 -0.34 -0.7 -0.73 -0.82 -0.56 -0.66 -0.63 4.62 -0.71 -0.63 -0.62
EBITDA
-17.04M -22.09M -23.24M -23.12M -23.44M -27.36M -24.61M -16.22M -31.17M -32.46M -25.97M -27.42M -28.37M -26.99M -26.82M -24.72M -21.83M -21.73M
EBIT
-17.94M -22.91M -24M -23.85M -24.23M -28.19M -25.46M -17.08M -32.05M -33.32M -28.89M -28.26M -29.19M -27.8M -28.72M -25.58M -22.62M -22.5M
Depreciation & Amortization
900K 827K 761K 733K 791K 835K 852K 864K 2.17M 859K 2.92M 1.1M 1.96M 1.93M 1.9M 1.9M 1.88M 1.83M